IPSEN (OTCMKTS:IPSEY) Sees Large Volume Increase – What’s Next?

IPSEN (OTCMKTS:IPSEY) shares saw unusually-high trading volume on Tuesday . Approximately 10,267 shares were traded during mid-day trading, an increase of 447% from the previous session’s volume of 1,878 shares.The stock last traded at $45.91 and had previously closed at $47.60.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Zacks Research upgraded IPSEN to a “hold” rating in a report on Friday, May 29th. HC Wainwright restated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Jefferies Financial Group lowered shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Barclays cut shares of IPSEN from an “equal weight” rating to an “underweight” rating in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

IPSEN Stock Down 6.6%

The stock’s 50-day moving average price is $46.61 and its 200 day moving average price is $46.76.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).